Who Actually Owns a University Spinout? The Equity Story Behind the Science
Before a spinout sells a single product, its ownership is already being carved up between the university, the founders and outside investors, and that split shapes everything that follows.
Why ownership is decided before the company even exists
Most explanations of university spinouts focus on the science: a discovery in a lab, a licence, a new company formed to commercialise it. Less visible, but arguably more consequential, is what happens on the cap table. Long before a spinout has customers or revenue, its shares have usually already been divided between the university (via its technology transfer office, or TTO), the academic founders, and sometimes early investors. That initial split determines how much control the founders retain, how attractive the company looks to future investors, and whether the people who did the underlying research have any real incentive to stay involved.
Why the university takes equity at all
When research is carried out using university facilities, funding or staff time, the resulting intellectual property is usually owned by the university under its IP policy, not by the individual academic. To let a spinout use that IP, the university typically grants an exclusive licence, or sometimes assigns the IP outright, in exchange for a stake in the new company plus, often, a right to royalties on future sales. This isn’t the university being greedy; it reflects that public money and public infrastructure helped create the invention, and the university has a duty (often tied to funders like UKRI) to see that value returned to the public interest, whether that’s through jobs, tax revenue or reinvestment in further research.
The size of that stake varies enormously between institutions and deals, but it is a live and often contentious issue in UK innovation policy. There has been sustained debate, including through initiatives such as the UK’s University Spin-out Review, about whether some universities took equity stakes so large that they discouraged founders and outside investors from engaging at all. In response, many institutions have moved towards more founder-friendly norms, but there is no fixed national rate, so anyone assessing a spinout deal needs to look at the specific term sheet, not assume a standard split.
The founders’ side: sweat equity and its limits
Academic founders typically receive shares in return for their expertise, their willingness to leave (or partly leave) academic roles, and their commitment to build the business, often called sweat equity because it’s earned through effort rather than paid in cash. But founder shares usually come with conditions: vesting schedules that release the equity gradually over several years, provisions that claw back shares if a founder leaves early, and sometimes restrictions on outside consulting. These protect the company from a scenario where a founder takes a large stake and then disengages, but they also mean a founder’s paper wealth is more conditional than it might first appear.
A separate complication is that academics often want to keep one foot in the university, continuing to teach, supervise students or publish, while also running or advising the company. Universities generally have conflict-of-interest policies governing how much time and involvement is allowed, and getting this wrong can create tension between a founder’s academic employer and their commercial venture.
Why dilution changes the picture fast
Whatever the founding split looks like, it rarely stays that way. Spinouts, particularly in deep tech and life sciences, tend to need multiple rounds of external investment before they generate significant revenue, because the underlying science often requires years of further development, testing or regulatory approval. Each funding round typically involves issuing new shares to investors, which dilutes the existing holders, including the university and the founders, unless they invest further money themselves to maintain their percentage.
This is why the initial equity split matters less in isolation than how it behaves under dilution. A university with a very large early stake, or founders with a small one, can end up in a much weaker position after two or three funding rounds. Investors evaluating a spinout will often look closely at the cap table history to judge whether the incentives are still aligned: are the people who understand the science motivated to stay, or has their stake been diluted to the point of indifference?
Governance: who actually makes decisions
Equity size doesn’t automatically equal control. Shareholder agreements typically specify board seats, voting rights on major decisions, and sometimes special rights retained by the university, such as consent over further IP licensing or a say if the company is sold. Founders can hold a meaningful equity percentage while still having limited board influence, particularly once professional investors join and typically expect board representation as a condition of funding.
What to check if you’re assessing a spinout
For journalists, investors or prospective employees trying to understand a spinout’s prospects, the useful questions are: what is the current cap table split between university, founders and investors; what vesting and leaver provisions apply to founder shares; and what governance rights does the university retain. None of these figures are standard across the sector, and they change with each funding round, so they should be checked against the specific company’s filings and agreements rather than assumed from general practice.
Where to check current detail
For policy context and current guidance on how UK universities structure spinout equity, see the UK Research and Innovation and gov.uk pages on university spinouts and the Spin-out Review, alongside individual university technology transfer office policies, which is where the specific figures relevant to any given deal will actually be published.